AntengeneFRA:722 +3.31%40 Days Payable is 163.54 as of Dec. 2025, which is 39% above its 10-year median of 117.54. GuruFocus rates FRA:722 with a GF Score™ of 40/100 and a GF Value™ of €0.15. The stock has 5 warning signs investors should review. Among 703 Biotechnology companies, Antengene ranks worse than 50.21% on this metric.
Antengene's average Accounts Payable for the
six
months ended in Dec. 2025 was €0.76 Mil. Antengene's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €0.85 Mil.
Hence, Antengene's Days Payable for the
six
months ended in Dec. 2025 was 163.54.
The historical rank and industry rank for Antengene's Days Payable or its related term are showing as below:
FRA:722'
s Days Payable Range Over the Past 10 Years
Min: 61.24 Med: 117.54 Max: 175.82
Current: 113.36
During the past 8 years, Antengene's highest Days Payable was 175.82. The lowest was 61.24. And the median was 117.54.
FRA:722's Days Payable is ranked worse than 50.21% of 703
companies
in the Biotechnology industry
Industry Median: 113.76
vs FRA:722: 113.36
Antengene's Days Payable
increased
from Dec. 2024 (79.88) to Dec. 2025 (163.54).
It may suggest that Antengenedelayed paying its suppliers.
Antengene Days Payable Related Terms
Antengene Days Payable Historical Data
* Premium members only.
The historical data trend for Antengene's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:722 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Antengene's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Antengene Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Antengene's Days Payable distribution charts can be found below:
* The bar in red indicates where Antengene's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Antengene's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antengene (FRA:722) has a Days Payable of 163.54 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Antengene and its competitors. This is 39% above median its historical median of 117.54. Over the past decade, Antengene's Days Payable has ranged from 61.24 to 175.82. According to the industry distribution chart, Antengene ranks #353 out of 703 companies in the Biotechnology industry, placing it in the top 50.2%.
Is Antengene's Days Payable too high?
Antengene's current Days Payable of 163.54 is 39% above median its 10-year median of 117.54. Over the past 10 years, this metric has ranged from a low of 61.24 to a high of 175.82. The Biotechnology industry median Days Payable is 113.76. Antengene's value of 163.54 is 43.8% above this industry median. Based on the distribution chart, Antengene ranks #353 out of 703 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Antengene has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Antengene's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Antengene ranks #353 out of 703 companies for Days Payable. This places Antengene in the lower half of its industry. The industry median Days Payable is 113.76. Antengene's value of 163.54 is 43.8% above this benchmark. Historically, Antengene's own Days Payable has ranged from 61.24 to 175.82 over the past decade. While the company's 10-year median is 117.54 vs. the industry median of 113.76, Antengene has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Antengene's current Days Payable of 163.54 is 43.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Antengene and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Antengene's current Days Payable is 163.54, which is 39% above median its own 10-year median of 117.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antengene stock overvalued right now?
Antengene (FRA:722) has a current Days Payable of 163.54. The stock's GF Value™ is €0.15, compared to a current price of €0.37 — trading 149.3% above its estimated fair value. The current Days Payable is 163.54, which is 39% above median its 10-year median of 117.54 and 43.8% above the Biotechnology industry median of 113.76. Antengene's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Antengene (FRA:722), the current Days Payable is 163.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Antengene (FRA:722) Overvalued in 2026?
Based on GuruFocus' analysis, Antengene stock appears to be overvalued.
The current stock price of €0.37 is trading 149.3% above its estimated GF Value™ of €0.15.
Key valuation signals for FRA:722:
Days Payable: 163.54 (39% above median its 10-year median of 117.54)
GF Value™: €0.15 vs. price of €0.37 (149.3% above fair value)
Industry Position: 43.8% above the Biotechnology median (#353 of 703)
No single metric tells the full story. See the FRA:722 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically, it operates in the Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
40GF Score
Get the complete analysis for FRA:722
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:722 has been successfully added to your 
